TLDR Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
This case report discusses a pediatric patient with alopecia universalis who experienced successful treatment with ritlecitinib after baricitinib failed. Alopecia areata in children is challenging to treat and often recurs, causing significant distress. Current treatments have limited efficacy and many side effects. This is the first documented case of a child transitioning from baricitinib to ritlecitinib, leading to positive clinical outcomes, marking a significant advancement in treating chronic severe alopecia areata in children.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
25 citations
,
December 2015 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.
421 citations
,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
10 citations
,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
May 2025 in “Frontiers in Pharmacology” New treatments are needed for non-scarring alopecia due to current limitations.
